(VIANEWS) – Choice Hotels International (CHH), iRadimed Corporation (IRMD), James River Group Holdings, Ltd. (JRVR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Choice Hotels International (CHH)
18.3% sales growth and 175.63% return on equity
Choice Hotels International, Inc., together with its subsidiaries, operates as a hotel franchisor worldwide. The company operates in Hotel Franchising and Corporate & Other segments. It franchises lodging properties under the brand names of Comfort Inn, Comfort Suites, Quality, Clarion, Clarion Pointe, Sleep Inn, Econo Lodge, Rodeway Inn, MainStay Suites, Suburban Extended Stay Hotel, WoodSpring Suites, Everhome Suites, Cambria Hotels, and Ascend Hotel Collection. The company also develops and markets cloud-based property management software to non-franchised hoteliers. As of December 31, 2020, it had 7,147 hotels with 597,977 rooms located in 50 states, the District of Columbia and approximately 40 countries and territories. The company was founded in 1939 and is based in Rockville, Maryland.
Earnings Per Share
As for profitability, Choice Hotels International has a trailing twelve months EPS of $5.84.
PE Ratio
Choice Hotels International has a trailing twelve months price to earnings ratio of 22.06. Meaning, the purchaser of the share is investing $22.06 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 175.63%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 23.7%, now sitting on 730.28M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Choice Hotels International’s EBITDA is 71.78.
Volume
Today’s last reported volume for Choice Hotels International is 480614 which is 6.04% below its average volume of 511524.
Sales Growth
Choice Hotels International’s sales growth is 13.8% for the ongoing quarter and 18.3% for the next.
2. iRadimed Corporation (IRMD)
12.8% sales growth and 21.67% return on equity
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Earnings Per Share
As for profitability, iRadimed Corporation has a trailing twelve months EPS of $1.06.
PE Ratio
iRadimed Corporation has a trailing twelve months price to earnings ratio of 45.68. Meaning, the purchaser of the share is investing $45.68 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.67%.
Volume
Today’s last reported volume for iRadimed Corporation is 14886 which is 57.22% below its average volume of 34798.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 17.2% and 12.5%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
iRadimed Corporation’s EBITDA is 104.98.
3. James River Group Holdings, Ltd. (JRVR)
10.3% sales growth and 3.97% return on equity
James River Group Holdings, Ltd., through its subsidiaries, provides specialty insurance and reinsurance services in the United States. It operates through Excess and Surplus Lines, Specialty Admitted Insurance, and Casualty Reinsurance segments. The Excess and Surplus Lines segment underwrites liability and property insurance on an excess and surplus commercial lines basis in all states and the District of Columbia. This segment distributes its insurance policies primarily through wholesale insurance brokers. The Specialty Admitted Insurance segment provides workers' compensation coverage for building trades, healthcare employees, goods and services, light manufacturing, specialty transportation, and agriculture, as well as fronting and program business. The Casualty Reinsurance segment offers proportional and working layer casualty reinsurance to third parties and other insurance companies. James River Group Holdings, Ltd. was founded in 2002 and is headquartered in Pembroke, Bermuda.
Earnings Per Share
As for profitability, James River Group Holdings, Ltd. has a trailing twelve months EPS of $0.52.
PE Ratio
James River Group Holdings, Ltd. has a trailing twelve months price to earnings ratio of 34.06. Meaning, the purchaser of the share is investing $34.06 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.97%.
Yearly Top and Bottom Value
James River Group Holdings, Ltd.’s stock is valued at $17.71 at 16:22 EST, way under its 52-week high of $26.60 and higher than its 52-week low of $16.74.
4. Vertex Pharmaceuticals (VRTX)
10.2% sales growth and 25.73% return on equity
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Earnings Per Share
As for profitability, Vertex Pharmaceuticals has a trailing twelve months EPS of $12.57.
PE Ratio
Vertex Pharmaceuticals has a trailing twelve months price to earnings ratio of 27.42. Meaning, the purchaser of the share is investing $27.42 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.73%.
Volume
Today’s last reported volume for Vertex Pharmaceuticals is 371533 which is 71.08% below its average volume of 1285070.
Yearly Top and Bottom Value
Vertex Pharmaceuticals’s stock is valued at $344.73 at 16:22 EST, under its 52-week high of $367.00 and way higher than its 52-week low of $271.61.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is 7.8% and a drop 2.7% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Vertex Pharmaceuticals’s EBITDA is 78.92.
